Characterization of four new designer drugs, 5-chloro-NNEI, NNEI indazole analog, α-PHPP and α-POP, with 11 newly distributed designer drugs in illegal products

被引：64

作者：

Uchiyama, Nahoko ^{[1
]}

Matsuda, Satoru ^{[1
]}

Kawamura, Maiko ^{[1
]}

Shimokawa, Yoshihiko ^{[1
]}

Kikura-Hanajiri, Ruri ^{[1
]}

Aritake, Kosuke ^{[2
]}

Urade, Yoshihiro ^{[2
]}

Goda, Yukihiro ^{[1
]}

机构：

[1] Natl Inst Hlth Sci, Setagaya Ku, Tokyo 1588501, Japan

[2] Osaka Biosci Inst, Dept Mol Behav Biol, Suita, Osaka 5650874, Japan

来源：

FORENSIC SCIENCE INTERNATIONAL | 2014年 / 243卷

关键词：

NNEI indazole analog; 5-Chloro-NNEI; 3,4-Dichloromethylphenidate; Synthetic cannabinoid; Cathinone derivative; SYNTHETIC CANNABINOIDS; DERIVATIVES; IDENTIFICATION; PREVALENCE; INHIBITORS; FUBINACA; JAPAN;

D O I：

10.1016/j.forsciint.2014.03.013

中图分类号：

DF [法律]; D9 [法律]; R [医药、卫生];

学科分类号：

0301 ; 10 ;

摘要：

Our continuous survey of illegal products in Japan revealed the new distribution of 15 designer drugs. We identified four synthetic cannabinoids, i.e., NNEI (1), 5-fluoro-NNEI (2), 5-chloro-NNEI (3) and NNEI indazole analog (4), and seven cathinone derivatives, i.e., MPHP (5), alpha-PHPP (6), alpha-POP (7), 3,4-dimethoxy-alpha-PVP (8), 4-fluoro-alpha-PVP (9), alpha-ethylaminopentiophenone (10) and N-ethyl-4-methylpentedrone (11). We also determined LY-2183240 (12) and its 2'-isomer (13), which were reported to inhibit endocannabinoid uptake, a methylphenidate analog, 3,4-dichloromethylphenidate (14), and an MDA analog, 5-APDB (15). No chemical and pharmaceutical data for compounds 3, 4, 6 and 7 had been reported, making this the first report on these compounds. (C) 2014 Elsevier Ireland Ltd. All rights reserved.

引用

页码：1 / 13

页数：13

共 19 条

[1]

[Anonymous], EMCDDA EUR 2012 ANN

[2] Novel indole and azaindole (pyrrolopyridine) cannabinoid (CB) receptor agonists: Design, synthesis, structure-activity relationships, physicochemical properties and biological activity [J].

Blaazer, Antoni R. ;

Lange, Jos H. M. ;

van der Neut, Martina A. W. ;

Mulder, Arie ;

den Boon, Femke S. ;

Werkman, Taco R. ;

Kruse, Chris G. ;

Wadman, Wytse J. .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2011, 46 (10) :5086-5098

[3]

Boehringer Ingelheim GMBH, 1967, Great Britain patent GB, Patent No. [1069797 19670524, 1069797]

[4]

Kikura-Hanajiri R., DRUG TEST ANAL

[5] Changes in the prevalence of synthetic cannabinoids and cathinone derivatives in Japan until early 2012 [J].

Kikura-Hanajiri, Ruri ;

Uchiyama, Nahoko ;

Kawamura, Maiko ;

Goda, Yukihiro .

FORENSIC TOXICOLOGY, 2013, 31 (01) :44-53

[6] Prevalence of New Designer Drugs and Their Legal Status in Japan [J].

Kikura-Hanajiri, Ruri ;

Uchiyama, Nahoko ;

Kawamura, Maiko ;

Ogata, Jun ;

Goda, Yukihiro .

YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN, 2013, 133 (01) :31-40

[7] 1-(4-methylphenyl)-2-pyrrolidin-1-yl-pentan-1-one (pyrovalerone) analogues: A promising class of monoamine uptake inhibitors [J].

Meltzer, PC ;

Butler, D ;

Deschamps, JR ;

Madras, BK .

JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (04) :1420-1432

[8] SYNTHESIS AND PHARMACOLOGICAL EXAMINATION OF BENZOFURAN, INDAN, AND TETRALIN ANALOGS OF 3,4-(METHYLENEDIOXY)AMPHETAMINE [J].

MONTE, AP ;

MARONALEWICKA, D ;

COZZI, NV ;

NICHOLS, DE .

JOURNAL OF MEDICINAL CHEMISTRY, 1993, 36 (23) :3700-3706

[9] Identification of a high-affinity binding site involved in the transport of endocannabinoids [J].

Moore, SA ;

Nomikos, GG ;

Dickason-Chesterfield, AK ;

Schober, DA ;

Schaus, JM ;

Ying, BP ;

Xu, YC ;

Phebus, L ;

Simmons, RMA ;

Li, D ;

Iyengar, S ;

Felder, CC .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (49) :17852-17857

[10] Carbamoyl tetrazoles as inhibitors of endocannabinoid inactivation: A critical revisitation [J].

Ortar, Giorgio ;

Cascio, Maria Grazia ;

Moriello, Aniello Schiano ;

Camalli, Mercedes ;

Morera, Enrico ;

Nalli, Marianna ;

Di Marzo, Vincenzo .

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2008, 43 (01) :62-72

← 1 2 →